Author Interviews, PLoS / 19.02.2015
Illicit Marketing Practices of UK, Swedish Pharmaceutical Companies Outlined
MedicalResearch.com Interview with:
Shai Mulinari Researcher, PhD
Sociology, Lund University
Medical Research: What is the background for this study? What are the main findings?
Dr. Mulinari : Over the past decade, several so-called whistleblower cases have spotlighted the illicit marketing practices of pharmaceutical companies in the US but relatively few similar cases have been brought in Europe. The reason for this discrepancy is unclear but one possibility is that the wider use of self-regulation in Europe encourages companies to comply with drug promotion rules and deters illicit conduct. But to date self-regulation of medicines promotion has been poorly studied.
We therefore investigated pharmaceutical industry self-regulation in the UK and Sweden. These are two countries often cited as places where self-regulation is effective. One of things that we found was that between 2004 and 2012 the Swedish and UK self-regulatory bodies ruled that 536 and 597 cases, respectively, were in breach of the country’s rules on medicines promotion; many of the violations in both countries concerned misleading claims about a drug’s effects. This equates to an average of more than one case per week in each country.
Charges incurred by companies because of these violations were equivalent to about 0.014% and 0.0051% of annual sales revenue in Sweden and the UK, respectively. Notably, nearly 20% of the cases in breach of the code of conduct in both countries were serious breaches.
(more…)